The management and board of dual-listed cancer diagnostics company Pacific Edge say everything is on the table as it reviews its strategy following the "surprising and disappointing" decision its Cxbladder tests will no longer be covered by US national health insurance provider Medicare.
But they
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
